Identification and characterization of genetic variation in the folylpolyglutamate synthase gene

Cancer Research

Volumn 67, Issue 18, 2007, Pages 8772-8782

  Leil, Tarek A ^a   Endo, Chiaki ^b   Adjei, Araba A ^c   Dy, Grace K ^c   Salavaggione, Oreste E ^d   Reid, Joel R ^a   Ames, Matthew M ^a   Adjei, Alex A ^c,d  

^a MAYO CLINIC   (United States)

^b TOHOKU UNIVERSITY   (Japan)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ARGININE; CYSTEINE; FOLIC ACID; FOLYLPOLYGLUTAMATE SYNTHASE; GLUTAMIC ACID; ISOLEUCINE; LEUCINE; METHOTREXATE; PEMETREXED; PHENYLALANINE; SERINE; VALINE;

AMINO ACID SEQUENCE; ARTICLE; CELL LINE; CYTOSOL; ENZYME ACTIVITY; FPGS GENE; GENE; GENE SEQUENCE; HUMAN; IC 50; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

BASE SEQUENCE; CYTOSOL; EXONS; FOLIC ACID; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HAPLOTYPES; HUMANS; KINETICS; METHOTREXATE; PEPTIDE SYNTHASES; POLYMORPHISM, SINGLE NUCLEOTIDE; SUBSTRATE SPECIFICITY; VARIATION (GENETICS);

EID: 34548771298     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0156     Document Type: Article

References (41)

1. Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA. The pharmacology and clinical use of methotrexate. N Engl J Med 1983;309:1094-104.
2. Adjei AA. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res 2004;10:4276-80s.
3. Mendelsohn LG, Shih C, Chen VJ, Habeck LL, Gates SB, Shackelford KA. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol 1999;26:42-7.
4. Kumar P, Kisliuk RL, Gaumont Y, Freisheim JH, Nair MG. Inhibition of human dihydrofolate reductase by antifolyl polyglutamates. Biochem Pharmacol 1989;38:541-3.
5. Zhao R, Goldman ID. Resistance to antifolates. Oncogene 2003;22:7431-57.
6. Moran RG, Werkheiser WC, Zakrzewski SF. Folate metabolism in mammalian cells in culture. I. Partial characterization of the folate derivatives present in L1210 mouse leukemia cells. J Biol Chem 1976;251:3569-75.
7. Schirch V, Strong WB. Interaction of folylpolyglutamates with enzymes in one-carbon metabolism. Arch Biochem Biophys 1989;269:371-80.
8. Shih C, Habeck LL, Mendelsohn LG, Chen VJ, Schultz RM. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul 1998;38:135-52.
9. Whitehead VM, Rosenblatt DS, Vuchich MJ, Shuster JJ, Witte A, Beaulieu D. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis. Blood 1990;76:44-9.
10. Masson E, Relling MV, Synold TW, et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest 1996;97:73-80.
11. UCSC Genome Browser. 2006. Available from: http://www.genome.ucsc.edu/ cgi-bin/htGateway.
12. Taylor SM, Freemantle SJ, Moran RG. Structural organization of the human folypoly-γ-glutamate synthetase gene: evidence for a single genomic locus. Cancer Res 1995;55:6030-4.
13. Freemantle SJ, Taylor SM, Krystal G, Moran RG. Upstream organization of and multiple transcripts from the human folylpoly-γ-glutamate synthetase gene. J Biol Chem 1995;270:9579-84.
14. Wang Y, Zhao R, Goldman ID. Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line. Biochem Pharmacol 2003;65:1163-70.
15. El-Fadili A, Richard D, Kundig C, Ouellette M. Effect of polyglutamylation of methotrexate on its accumulation and the development of resistance in the protozoan parasite Leishmania. Biochem Pharmacol 2003;66:999-1008.
16. Zhao R, Titus S, Gao F, Moran RG, Goldman ID. Molecular analysis of murine leukemia cell lines resistant to 5,10-dideazatetrahydrofolate identifies several amino acids critical to the function of folylpolyglutamate synthetase. J Biol Chem 2000;275:26599-606.
17. Liani E, Rothem L, Bunni MA, Smith CA, Jansen G, Assaraf YG. Loss of folylpoly-γ-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer 2003;103:587-99.
18. Ma CX, Adjei AA, Salavaggione OE, et al. Human aromatase: gene resequencing and functional genomics. Cancer Res 2005;65:11071-82.
19. Sanghani PC, Moran RG. Purification and characteristics of recombinant human folylpoly-γ-glutamate synthetase expressed at high levels in insect cells. Protein Expr Purif 2000;18:36-45.
20. Turner FB, Taylor SM, Moran RG. Expression patterns of the multiple transcripts from the folylpolyglutamate synthetase gene in human leukemias and normal differentiated tissues. J Biol Chem 2000;275:35960-8.
21. Hartl DL, Clark AG. Organization of genetic variation. In: Principles of population genetics, Chapter 3. 3rd ed. Sunderland (MA): Sinauer Associates, Inc; 2000. p. 95-107.
22. Hendrick PW. Genetics of populations. 3rd ed. Sundbury (MA): Jones and Bartlett Publishers; 2000.
23. Tajima F. Statistical method for testing the neutral mutation hypothesis by DNA polymorphism. Genetics 1989;123:585-95.
24. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-34.
25. Fullerton SM, Clark AG, Weiss KM, et al. Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism. Am J Hum Genet 2000;67:881-900.
26. Sherry ST, Ward M, Sirotkin K. dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. Genome Res 1999;9:677-9.
27. Brodde OE, Leineweber K. β2-Adrenoceptor gene polymorphisms. Pharmacogenet Genomics 2005;15:267-75.
28. Drysdale CM, McGraw DW, Stack CB, et al. Complex promoter and coding region β2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A 2000;97:10483-8.
29. Taylor RT, Wu R, Hanna ML. Induced reversion of a Chinese hamster ovary triple auxotroph. Validation of the system with several mutagens. Mutat Res 1985;151:293-308.
30. Qi H, Atkinson I, Xiao S, Choi YJ, Tobimatsu T, Shane B. Folylpoly-γ-glutamate synthetase: generation of isozymes and the role in one carbon metabolism and antifolate cytotoxicity. Adv Enzyme Regul 1999;39:263-73.
31. Sun X, Bognar AL, Baker EN, Smith CA. Structural homologies with ATP- and folate-binding enzymes in the crystal structure of folylpolyglutamate synthetase. Proc Natl Acad Sci U S A 1998;95:6647-52.
32. Mathieu M, Debousker G, Vincent S, Viviani F, Bamas-Jacques N, Mikol V. Escherichia coli FolC structure reveals an unexpected dihydrofolate binding site providing an attractive target for anti-microbial therapy. J Biol Chem 2005;280:18916-22.
33. Young PG, Smith CA, Sun X, Baker EN, Metcalf P. Purification, crystallization and preliminary X-ray analysis of Mycobacterium tuberculosis folylpolyglutamate synthase (MtbFPGS). Acta Crystallograph Sect F Struct Biol Cryst Commun 2006;62:579-82.
34. Sun X, Cross JA, Bognar AL, Baker EN, Smith CA. Folate-binding triggers the activation of folylpolyglutamate synthetase. J Mol Biol 2001;310:1067-78.
35. Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: an automated protein homology-modeling server. 2003 [cited 2006; Available from: http://swissmodel. expasy.org/.
36. Smith CA, Cross JA, Bognar AL, Sun X. Mutation of Gly51 to serine in the P-loop of Lactobacillus casei folylpolyglutamate synthetase abolishes activity by altering the conformation of two adjacent loops. Acta Crystallogr D Biol Crystallogr 2006;62:548-58.
37. Sheng Y, Cross JA, Shen Y, Smith CA, Bognar AL. Mutation of an essential glutamate residue in folylpolyglutamate synthetase and activation of the enzyme by pteroate binding. Arch Biochem Biophys 2002;402:94-103.
38. Wang L, Yee VC, Weinshilboum RM. Aggresome formation and pharmacogenetics: sulfotransferase 1A3 as a model system. Biochem Biophys Res Commun 2004;325:426-33.
39. Ji Y, Salavaggione OE, Wang L, et al. Human phenylethanolamine N-methyltransferase pharmacogenomics: gene re-sequencing and functional genomics. J Neurochem 2005;95:1766-76.
40. Mukherjee B, Salavaggione OE, Pelleymounter LL, et al. Glutathione S-transferase ω1 and ω2 pharmacogenomics. Drug Metab Dispos 2006;34:1237-46.
41. Wang L, Sullivan W, Toft D, Weinshilboum R. Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation. Pharmacogenetics 2003;13:555-64.